Good morning everyone. I'm very excited for today's episode because we're going to talk about how clinical evidence is going to be synthesized in the new age of artificial intelligence. As usual, very grateful to our experts here Ed Marx who always talks about how to bravely go where no one has gone before. When I see him, I feel about Star Trek. And then the idea is essentially adding new forms of intelligence and then how to really implement it. His guidance is always important for practical purposes. And then of course, Harvey, who brings in not only US experience, but international experience of artificial intelligence implementation. Now we're going to set up what we're going to discuss today, accelerating clinical evidence synthesis with large language models. And we truly believe that clinical evidence is far behind in the normal thing. So let me set the stage. stroke physician, know, the main medication was TPA. Believe it or not, NIH approved that through FDA, I think to only 250 patients or so. That's it. That was annoying. And then we realized it is way more better what the clinical trial results were. Then we got a new medication called TNK, Teniplectis. Now that Teniplectis is a bolus, is, know, the practicality was amazing, but still to this day, there is no clinical guidelines that are supporting it properly. I mean, they just gave an update of the results. So it took them seven years to actually update the guidelines. And then in the meanwhile, in some of these cases, in the first two to three years, people like us were living, you know, making sure we had to disclose to patients that it is not FDA approved in the sense of this exact indication, but we have significant evidence, blah, blah, blah. And therefore, I want to give it to you. There was an additional nuisance that we had to do. And then finally, somebody did the study, then that evidence was approved by FDA, and then they put it into the drug indication. Remember, drugs has indications of use as well. So three issues. Number one, we who are doing clinical work are producing evidence, period. What we want to do is we want to use that clinical evidence on a daily basis to create actual publishable results and then more importantly, effect policy change. So this article goes into an amazing way of how we can go ahead and do that. So first, Harvey can set this stage. Why do we lack so much in clinical evidence? And then add can set the stage why from a CIO, CTO perspective, what is the current sort of bottlenecks, and then we can go into possible solutions according to this paper. So, Hari, go ahead.